IP Library Granted Patent US 11,261,183
Granted Patent B2
US 11,261,183 · App. 16/488,139 · Granted Mar 1, 2022

Sulfoximine glycosidase inhibitors

Inventors: Anna Quattropani (Rolle, CH); Santosh S. Kulkarni (Bangalore, IN); Awadut Gajendra Giri (Bangalore, IN)
Assignee: Asceneuron SA
C07D471/04A61K9/0019A61K9/0048A61K9/0073A61K9/02A61K9/06A61K9/19A61K9/2009A61K9/2059A61K9/4825A61K31/496A61K31/497A61K31/4985A61P25/28C07D401/12C07D401/14C07D403/12C07D405/06C07D405/10C07D405/12C07D405/14C07D407/12C07D413/12C07D413/14C07D417/06C07D417/12C07D417/14C07D475/04C07D487/04C07D491/048C07D495/04C07D498/04C07D513/04C07B2200/09
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,183
App. No.
16/488,139
Granted
Mar 1, 2022
Kind
B2
Abstract

Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Claims (4)

1. A compound, (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1-yl)pyrimidin-5-yl) (imino)(methyl)-λ 6 -sulfanone,

or a tautomer, enantiomer, racemate, stereoisomer, or a compound of the above formula wherein one or more H atoms are replaced by D (deuterium), including mixtures thereof in all ratios.

2. A pharmaceutically usable salt of (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1-yl)pyrimidin-5-yl) (imino)(methyl)-λ 6 -sulfanone or any of its tautomers, enantiomers, racemates or stereoisomers.

3. The pharmaceutically usable salt of the compound of claim 2 , or any of its tautomers or enantiomers, racemates or stereoisomers, wherein the pharmaceutically acceptable salt is acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprate, caprylate, chloride, chlorobenzoate, citrate, cyclamate, cinnamate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, glycolate, fumarate, galacterate, galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate or phthalate.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 19, 2025
From: KREOS CAPITAL VI (UK) LIMITED
To: ASCENEURON SA
Reel/Frame 070252/0136 →
SECURITY INTEREST Recorded Mar 22, 2022
From: ASCENEURON SA
To: KREOS CAPITAL VI (UK) LIMITED
Reel/Frame 059337/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: QUATTROPANI, ANNA; KULKARNI, SANTOSH S.; GIRI, AWADUT GAJENDRA
To: ASCENEURON SA
Reel/Frame 051170/0826 →
Priority Claims (2)
IN 201621006636 · Feb 25, 2016 · national
IN 201621006643 · Feb 25, 2016 · national
Continuity (3)
Continuation In Part PCTEP2017054268 · Feb 24, 2017
Continuation In Part PCTEP2017054280 · Feb 24, 2017
Related Publication 20200002326A1 · Jan 2, 2020
Cited By (3)
US 12,187,741 US 12,195,455 US 12,398,130